（原标题：突然大爆发，601606股价创新高！这一领域迎利好，主力资金抢筹股出炉） 我国脑机接口正处于由基础研究向临床应用转化的重要阶段。 7月31日，市场全天震荡调整，三大股指午后均跌超1%。算力概念股活跃，英维克、川润股份等多股涨 停。创新药概念延续强势，钢铁、煤炭等周期股集体调整，油气、有色金属等板块跌幅居前。 军工股尾盘爆发，长城军工(601606)涨停再创新高，北方长龙涨17.22%，捷强装备、内蒙一机等个股尾 盘快速上涨。 国家医保局支持脑机接口等新技术进入临床并收费 据央视新闻报道，为支持药品和医疗器械创新发展，国家医保局制定新上市药品首发价格机制，新增了 100多项与医疗新技术相关的价格项目。国家医保局从立项、定价等方面入手，畅通新技术的收费通 道，助力满足临床急需的新技术新产品加快收益回报。 | | | 主力资金净流入额居前的脑机接口概念股一览 | | | | --- | --- | --- | --- | --- | | 代码 | 简称 | 总市值 (亿元) | 年内涨跌幅 (%) | 7月31日丰力 净流入额 | | 300418 | 昆仑万维 | 450.67 | -6.70 | (亿 ...

尾盘，再现异动！ 7月31日，A股三大指数集体调整，截至今日收盘，沪指下跌1.18%，深证成指跌1.73%，创业板指跌1.66%。从盘面上看，钢铁、煤 炭、有色等前期过热的板块集体大跌，AI、创新药概念股则逆市上涨。 值得关注的是，临近收盘时，创新医疗、爱朋医疗、三博脑科等多只脑机接口概念股直线拉升，创新医疗一度逼近涨停。从消息面来 看，当天下午，脑机接口板块迎来一则利好消息。据报道，国家医保局支持脑机接口等新技术进入临床并收费。 脑机接口概念股尾盘拉升 7月31日，临近A股尾盘时分，多只脑机接口概念股突然直线拉升，创新医疗涨幅一度达到9.62%，爱朋医疗一度涨超9%，三博脑科、 倍益康、熵基科技、南京熊猫等相关概念股均有拉升动作。 | 壳价 叠加 重播 统计 | | 分时 1分钟 5分钟 15分钟 30分钟 60分钟 日线 更多 > | | 画线 F10 | 标记 -自选 返回 | | 创新医疗 002173 | | | | 医疗保健 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 创新医疗 分时 ...

延伸阅读： 2024年1至12月份，创新医疗的营业收入构成为：医疗服务业务占比99.52%，其他业务占比0.48%。 截至发稿，创新医疗市值为63亿元。 每经AI快讯，创新医疗（SZ 002173）7月30日晚间发布公告称，经马建建总裁提名，公司董事会同意聘 任杨建荣为公司财务总监。 ST宁科:聘任金相宇为公司财务总监 宝馨科技徐业香辞去公司董事、财务总监职务 延江股份:聘任刘培源为公司财务总监 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300683 | 海特生物 | 56.33 | 8.37% | 17.94万 | | 10.12亿 | | 002173 | 创新医疗 | 15.34 | 7.72% | 76.57万 | | 11.37亿 | | 301096 | 百诚医药 | 58.45 | 7.09% | 17.58万 | | 10.01亿 | | 000710 | 贝瑞基因 | 14.64 | 4.95% | 56.75万 | | 8.30亿 | | 301293 | 三博脑科 | 50.08 | 3.58% | 14.57万 | | 7.19 Z | | 300149 | 睿智医药 | 14.24 | 3.56% | 134.38万 | | 18.69亿 | | 000504 | *ST生物 | 10.67 | 3.39% | 5.73万 | | 6098.79万 | | 300244 | 迪安诊断 | 16.10 | 1.58% | 37.94万 | | ...

7月31日，人脑工程概念上涨0.27%，今日主力资金流入7729.22万元，概念股14只上涨，19只下跌。 主力资金净流入居前的分别为科大讯飞（2.28亿元）、创新医疗（9399.58万元）、乐普医疗（6230.96 万元）、熵基科技（6031.32万元）、爱朋医疗（3162.54万元）。 来源：金融界 序号代码名称最新价涨跌幅主力净流入主力净占比1002230科大讯飞48.780.762.28亿元8.28%2002173创 新医疗15.347.729399.58万元8.27%3300003乐普医疗15.560.846230.96万元5.49%4301330熵基科技 29.213.86031.32万元12.2%5300753爱朋医疗31.397.283162.54万元5.27%6002195岩山科技5.741.232957.49 万元1.87%7301293三博脑科50.083.582790.86万元3.88%8603610麒盛科技12.662.592028.90万元 9.16%9300678中科信息33.980.651515.56万元3.66%10688273麦澜德33.76-0.591193.99万元9. ...

资金流向方面，今日主力资金净流入9399.58万元，占比成交额8.27%。其中，超大单净流入1.09亿元、 占成交额9.56%，大单净流出1477.02万元、占成交额1.3%，中单净流出流出5820.40万元、占成交额 5.12%，小单净流出3579.17万元、占成交额3.15%。 创新医疗最新一期业绩显示，截至2025一季报，公司营业总收入1.93亿元、同比减少3.98%，归属净利 润1393.74万元，同比减少368.03%，扣非净利润1497.05万元，同比减少452.67%，流动比率1.892、速动 比率1.780、资产负债率18.52%。 天眼查商业履历信息显示，创新医疗管理股份有限公司，成立于2003年，位于绍兴市，是一家以从事卫 生为主的企业。企业注册资本44128.4352万人民币。公司法定代表人为陈海军。 通过天眼查大数据分析，创新医疗管理股份有限公司共对外投资了9家企业，参与招投标项目6次，专利 信息18条，此外企业还拥有行政许可6个。 来源：金融界 金融界消息 截至2025年7月31日收盘，创新医疗（002173）报收于15.34元，上涨7.72%，换手率 18.39%，成交量76.57 ...

Core Viewpoint - The news highlights a significant rise in brain-computer interface (BCI) concept stocks, driven by new pricing mechanisms introduced by the National Healthcare Security Administration (NHSA) to support innovation in pharmaceuticals and medical devices [1] Group 1: Market Reaction - BCI-related stocks such as Innovation Medical are nearing their daily limit up, with other companies like Aipeng Medical, Sanbo Brain Science, Entropy Technology, Qisheng Technology, and Yanshan Technology also experiencing gains [1] Group 2: Policy Changes - The NHSA has established a new pricing mechanism for newly launched drugs, adding over 100 pricing items related to new medical technologies [1] - Specific pricing items for the nervous system have been introduced, including "BCI implantation fees" and "BCI adaptation fees," which will facilitate rapid clinical application and charging once BCI technology is approved for clinical use [1] - Guidelines for ear, nose, and throat (ENT) procedures now include pricing for "cochlear implant fees" and "speech device installation fees," encouraging medical institutions to assist more patients in communication [1] - Pricing items for radiation therapy have been standardized, including "proton therapy" and "heavy ion therapy," promoting the clinical application of advanced medical equipment [1]

消息面上，为支持药品和医疗器械创新发展，国家医保局制定新上市药品首发价格机制，新增了100多 项与医疗新技术相关的价格项目。神经系统类立项指南统一设立"脑机接口置入费""脑机接口适配费"等 价格项目，脑机接口技术成熟获批进入临床后，可快速进入临床应用并收费。耳鼻喉类立项指南统一设 立"人工耳蜗植入费""发音装置安装费"等价格项目，鼓励医疗机构帮助更多患者"听得见、说得出"。放 射治疗类立项指南统一设立"质子放疗""重离子放疗"等价格项目，促进高端医疗设备的临床转化应用。 与此同时，为鼓励药品研发创新，国家医保局还制定了新上市药品首发价格机制。 格隆汇7月31日｜脑机接口概念股拉升，其中，创新医疗逼近涨停，爱朋医疗、三博脑科、熵基科技、 麒盛科技、岩山科技等跟涨。 ...

A股脑机接口概念尾盘异动拉升，爱朋医疗涨超8%，创新医疗、优刻得-W、三博脑科等跟涨。消息面 上，据央视新闻报道，国家医保局支持脑机接口等新技术进入临床并收费。 ...

Group 1 - The core viewpoint of the article highlights that Shenzhen Silicon-based Bionic Technology Co., Ltd. has been awarded the "Best Innovative Medical Device Company of the Year" at the 9th Medical Health Investment Excellence List by Haoyue Capital, recognizing its outstanding performance in the innovative medical device sector [1][3] - The "Medical Health Investment Excellence List" is a prestigious evaluation created by Haoyue Capital, focusing on the comprehensive strength of investment institutions in the medical health industry, including activity levels, transaction volumes, return performance, and post-investment empowerment [3][4] - Silicon-based Bionic was founded in 2015 and specializes in blood glucose monitoring, utilizing implantable medical hardware technology and AI algorithms to innovate and promote continuous monitoring products globally [4][5] Group 2 - The company has a workforce of nearly 700, led by scientists from prestigious institutions such as Tsinghua University, Peking University, Caltech, Princeton, and the University of Washington, showcasing a strong research and operational management background [4][5] - Its flagship product, the Silicon-based Dynamic CGM, is the second globally and the first in China to use second-generation glucose sensor technology, achieving the highest sales among domestic CGM products for several consecutive years [4][5] - The company has made significant investments in R&D, participating in key national projects and being recognized as a "National High-Performance Medical Device Innovation Center" and a "Potential Technology Unicorn Enterprise" in Shenzhen [5][6] Group 3 - The Chinese medical health industry is experiencing a structural recovery in 2025, with increased financing activity and significant milestone transactions, indicating a shift towards high-quality, international, and value-driven medical innovation [5][6] - Silicon-based Bionic aims to uphold its core value of "Innovating Medical Technology, Serving Public Health" and aspires to become a global leader in chronic disease management innovative medical devices [6]